A5091523184- Acute Myeloid Leukemia Research
- Education, sociology, and vocational training
- Hematopoietic Stem Cell Transplantation
- Educational Practices and Policies
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Historical and Literary Analyses
- French Urban and Social Studies
- Historical and Literary Studies
- Historical Education and Society
- Lymphoma Diagnosis and Treatment
- Single-cell and spatial transcriptomics
- Biblical Studies and Interpretation
- French Language Learning Methods
- Historical Education Studies Worldwide
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Digital Imaging for Blood Diseases
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- European Political History Analysis
- French Historical and Cultural Studies
- Vascular Tumors and Angiosarcomas
Centre Hospitalier Universitaire de Bordeaux
2016-2025
Université de Bordeaux
1997-2022
Hôpital Cardiologique du Haut-Lévêque
1999-2021
University of Geneva
2015
Ordecsys (Switzerland)
2015
Institut Pasteur
1980-1995
Inserm
1992-1995
Hôpital Edouard Herriot
1995
Centre National de la Recherche Scientifique
1992
ABSTRACT Representing and quantifying Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML), a type of cancer that affects the blood bone marrow, is essential prognosis follow‐up AML patients. As traditional cytological analysis cannot detect leukemia cells below 5%, flow cytometry datasets expected to provide more reliable results. In this paper, we explore statistical learning methods based on optimal transport (OT) achieve relevant low‐dimensional representation multi‐patient...
Abstract Classifications of acute myeloid leukemia (AML) patients rely on morphologic, cytogenetic, and molecular features. Here we have established a novel flow cytometry-based immunophenotypic stratification showing that AML blasts are blocked at specific stages differentiation where features normal myelopoiesis preserved. Six differentiation-arrest categories based CD34, CD117, CD13, CD33, MPO, HLA-DR expression were identified in two independent cohorts 2087 1209 patients. Hematopoietic...
The assessment of minimal residual disease (MRD) is increasingly considered to monitor response therapy in hematological malignancies. In acute myeloblastic leukemia (AML), molecular MRD (mMRD) possible for about half the patients while multiparameter flow cytometry (MFC) more broadly available. However, MFC analysis strategies are highly operator-dependent. Recently, new tools have been designed unsupervised analysis, segregating cell-clusters with same immunophenotypic characteristics....
Abstract Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/ BCR::ABL1 , a distinct entity within the group of AML defining genetic abnormalities, belong to adverse-risk 2022 ELN classification. However, there is little data on outcome since era tyrosine kinase inhibitors. Among 5819 cases included in DATAML registry, 20 patients de novo + (0.3%) were identified. Eighteen treated standard induction chemotherapy analyzed this study. Imatinib was added 16 patients. The female-to-male...
Multiparameter flow cytometry (MFC) is a powerful and versatile tool to accurately analyze cell subsets, notably explore normal pathological hematopoiesis. Yet, mostly supervised subjective strategies are used identify subsets in this complex tissue. In the past few years, implementation of mass big data generated have led blossoming new software solutions. Their application classical MFC hematology however still seldom reported. Here, we show how one these tools, FlowSOM R solution, can be...
Acute myeloid leukemias (AML) are clonal diseases that develop from leukemic stem cells (LSC) carry an independent prognostic impact on the initial response to induction chemotherapy, demonstrating clinical relevance of LSC abundance in AML. In 2018, European LeukemiaNet published recommendations for detection measurable residual disease (Bulk MRD) and suggested exploration MRD use multiparametric displays.We evaluated performance unsupervised clustering post-induction assessment bulk 155...
We evaluated reticulocyte counting and measurement of immature fraction (IRF) with the ABX PENTRA 120 Retic blood analyzer on 300 samples. Reticulocyte counts were compared those obtained by visual 2,000 RBCs, TOA (Kobe, Japan) Sysmex R-2000 a flow cytometry method. The parameters analyzed percentages reticulocytes all analyzers IRF different modalities. Count kit (Becton Dickinson, San Jose, CA) was used Coulter (Hialech, FL) XL, mean channel fluorescence (MCF) calculated to fit maturation....
Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We performed retrospective study of 138 MDS patients with isolated +8, classified or reclassified as (excluding MDS/myeloproliferative neoplasm). Myeloproliferative (MP) features were defined by repeated presence one following: white blood cell count >10 × 109 /l, myelemia (presence circulating immature granulocytes predominance more mature forms)...
Abstract Postremission treatment is crucial to prevent relapse in acute myeloid leukemia (AML). High-dose cytarabine delivered every 12 hours on days 1, 3, and 5 (HDAC-135) the standard of care for younger adult patients with AML. Although this has been unsuccessfully challenged by other regimens, including multiagent chemotherapy, timing HDAC administration attracted little attention. Here, we retrospectively compared safety, efficacy, health resource consumption associated HDAC-135 another...
The complete blood cell count and white differential are the first step in biological diagnosis of hematological diseases. Both currently performed by automated instruments which control data produce alerts. If such flags activated, cannot be validated operator must activate a visual smear review. Microscopic examination is still today reference method despite its lack sensitivity reproducibility. HematoFlow™ (Beckman Coulter) system flow cytometry commercialized designed for routine...
Recent massive parallel sequencing data have evidenced the genetic diversity and complexity of Sézary syndrome mutational landscape with TP53 alterations being most prevalent abnormality. We analyzed a cohort 35 patients SS control group 8 chronic inflammatory dermatoses. status was at different clinical stages especially in 9 past-history mycosis fungoides (MF), coined secondary SS. mutations were only detected 10 either primary or (29%) corresponding to point mutations, small insertions...
A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) improved gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared standard care. In this trial, response rate therapy was particularly low. We retrospectively assessed characteristics and R/R AML included in Toulouse-Bordeaux DATAML registry. Among 347 who received TKI-free intensive chemotherapy as first-line treatment, 174...
Sezary syndrome (SS) is a rare leukemic form of cutaneous T-cell lymphoma. Diagnosis mainly depends on flow cytometry, but results are not specific enough to be unequivocal. The difficulty in defining single marker that could characterize cells may the consequence different pathological subtypes. In this study, we used multivariate cytometry analyses. We chose investigate expression classical CD3, CD4, CD7, and CD26 new association 2 markers CD158k PD-1. performed lymphocyte computational...
Risk stratification and treatment response evaluation are key features in acute myeloid leukemia (AML) management. Immunophenotypic molecular approaches all rely on the detection of persisting leukemic cells by measurable residual disease techniques. A new approach is proposed here assessing medullary maturation flow cytometry through a progenitor ratio (MPR). The normal MPR range was defined using reference bone marrows (
Abstract Background Acute myeloid leukemia (AML) with myelodysplasia‐related characteristics is a heterogeneous subset of AML that has been challenged throughout the history malignancies classifications, considered to have similar outcomes as intermediate‐ or adverse‐risk depending on subgroup. However, little known about fate these patients in refractory relapsed situation (R/R) after first line therapy. Methods A large series R/R patients, recorded French DATAML registry, received either...
Abstract According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate‐dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared efficacy mini‐consolidations (idarubicin 8 mg/m 2 day 1, 50 /12 h, 1–5) and IDAC. Inclusion criteria were newly diagnosed AML, age > 60 years, CR at least 1 cycle...
Two recent phase 3 trials showed that outcomes for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) patients may be improved by a single-agent tyrosine kinase inhibitor (TKI) (i.e., quizartinib or gilteritinib). In the current study, we retrospectively investigated characteristics and real-world of R/R FLT3-internal tandem duplication (ITD) in Toulouse-Bordeaux DATAML registry. included 316 with FLT3-ITD AML received intensive chemotherapy as first-line treatment. The rate...